Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Macrophages constitute the predominant infiltrating immune cells in the kidneys of patients with IgA nephropathy (IgAN) and are critically involved in its pathogenesis and progression. Integrin αM (CD11b), a primary surface marker of macrophages, can be shed from the cell membrane upon various stimuli, leading to elevated levels of soluble CD11b (sCD11b) in the urine (u-sCD11b). Previous studies in lupus nephritis and ANCA-associated glomerulonephritis have established that u-sCD11b reflects histopathological activity and aids in predicting treatment response. However, its role in IgAN remains undefined. This study aimed to investigate the potential of u-sCD11b for evaluating disease severity, predicting remission status, and its relation to immunosuppressive therapy in patients with IgAN.
In this retrospective cohort of 636 biopsy-proven IgAN patients, we analyzed the cross-sectional correlations of urinary soluble CD11b (u-sCD11b, measured by ELISA and creatinine-normalized) with histopathological and clinical parameters. Subsequently, we longitudinally assessed the predictive value of baseline u-sCD11b for remission status and eGFR change in a follow-up sub-cohort.
U-sCD11b levels correlated with renal macrophage infiltration in both glomerular and tubulointerstitial compartments. Higher u-sCD11b levels at the time of biopsy were associated with more severe histologic lesions, greater proteinuria, and worse renal function. After adjustment for age, sex, BMI, diabetes, hypertension, eGFR, Oxford MEST-C score, and immunosuppressive therapy, a high u-sCD11b level (≥3.49 ng/mg uCr) remained independently associated with a higher risk of failure to achieve remission at 3-month follow-up (odds ratio [OR] 2.09; 1.01-4.35; P for trend = 0.048). Finally, in a subgroup analysis of patients with high u-sCD11b levels, those who received immunosuppressive therapy exhibited a significantly slower decline in eGFR from baseline over a 2-year follow-up period compared to the untreated patients.
This study provides strong initial evidence that u-sCD11b levels are associated with clinical severity, active pathological lesions, and short-term remission status in IgAN. Furthermore, elevated u-sCD11b may signify active inflammatory states that warrant more aggressive immunosuppressive therapy. Collectively, our findings position u-sCD11b as a novel and valuable biomarker for assessing disease activity, predicting short-term outcomes, and informing management strategies in patients with IgAN.
